The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -26,856 | -59,431 |
| Depreciation and amortization expense | 1,573 | 3,335 |
| Noncash lease expense | 682 | 1,673 |
| Stock-based compensation expense | 2,529 | 6,088 |
| Loss on disposal of property and equipment | 0 | -103 |
| Net amortization of premiums and accretion discounts on investments | 705 | 2,176 |
| Amortization of deferred transaction costs | 0 | 15 |
| Prepaid expenses and other current assets | 619 | -1,109 |
| Other non-current assets | -116 | -188 |
| Accounts payable | 1,213 | -491 |
| Operating lease liabilities | -778 | -1,875 |
| Accrued and other current and non-current liabilities | 538 | -568 |
| Net cash used in operating activities | -22,307 | -52,030 |
| Purchases of short-term treasury securities | 26,955 | 34,369 |
| Maturities of short term treasury securities | -44,000 | -66,000 |
| Purchases of property and equipment | 209 | 1,539 |
| Net cash used in investing activities | 16,836 | 30,092 |
| Proceeds from issuance of common stock pursuant to at-the-market offering, net of issuance costs | 0 | 0 |
| Proceeds from issuance of common stock and pre-funded warrants pursuant to underwritten public offering, net of issuance costs | 0 | 0 |
| Proceeds from exercise of stock options | 0 | 0 |
| Proceeds from employee stock purchase plan | 0 | 267 |
| Taxes withheld and paid related to net share settlement of equity awards | 0 | -104 |
| Principal payments on finance leases | 150 | - |
| Net cash provided by financing activities | -150 | 163 |
| Net change in cash, cash equivalents and restricted cash | -5,621 | -21,775 |
| Cash and cash equivalents at beginning of period | 59,398 | - |
| Cash and cash equivalents at end of period | 32,002 | - |
Adicet Bio, Inc. (ACET)
Adicet Bio, Inc. (ACET)